Clinical Policy: Nerandomilast (Jascayd)
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.759 alerts
Get alerted when Policy CP.PHAR.759 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Jascayd in adult members with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis. It applies to QualChoice commercial, HIM/ICHRA, and Medicaid lines of business.
Progressive pulmonary fibrosis was added as a newly FDA-approved indication.
Step-therapy requirements were revised for IPF and PPF.
A rheumatologist was added as an eligible prescriber or consultant for PPF.
The health-plan-approved quantity-limit criterion was removed.
The HIM/ICHRA line of business was added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.